Detalhe da pesquisa
1.
Incidence, molecular characteristics, and imaging features of "clinically-defined pseudoprogression" in newly diagnosed glioblastoma treated with chemoradiation.
J Neurooncol
; 159(3): 509-518, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35842871
2.
Rate of change in maximum 18F-FDOPA PET uptake and non-enhancing tumor volume predict malignant transformation and overall survival in low-grade gliomas.
J Neurooncol
; 147(1): 135-145, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-31981013
3.
pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma.
J Neurooncol
; 142(3): 587-595, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30806888
4.
Head-to-head comparison of commercial artificial intelligence solutions for detection of large vessel occlusion at a comprehensive stroke center.
Front Neurol
; 13: 1026609, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36299266
5.
Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors.
Neuro Oncol
; 24(6): 1020-1028, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34865129
6.
Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma.
Neurooncol Adv
; 3(1): vdab082, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34377989
7.
Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden.
Neurosurgery
; 87(5): 931-938, 2020 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32365185